Form 4 for AMGN Amgen
Accepted 2023-05-04 00:00:00 ET · period of report 2023-05-02 · accession 0001127602-23-014612 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-04 | 2023-05-02 | AMGN | REESE DAVID M | EVP, Research, Development | A - Grant | $0.00 | +3,814 | 55.5K | +7% | $0 |
| D | 2023-05-04 | 2023-05-03 | AMGN | REESE DAVID M | EVP, Research, Development | F - Tax | $235.97 | -819 | 54.7K | -1% | -$193.3K |
| D | 2023-05-04 | 2023-05-02 | AMGN | REESE DAVID M | EVP, Research, Development | A - Grant | $0.00 | +32.2K | 32.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-02 | A | A | 3,814 | $0.00 | 55,527 | D | — | — | (F1) The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. |
| 2 | Common | Common Stock | 2023-05-03 | F | D | 819 | $235.97 | 54,708 | D | — | — | (F3) These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F2) These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |
| 3 | Derivative | Nqso (Right to Buy) | 2023-05-02 | A | A | 32,250 | $0.00 | 32,250 | D | $235.97 · 2025-05-02 to 2033-05-02 | 32,250 Common Stock | (F4) These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. |